1. Mäkitie O, Zillikens MC. Early-Onset Osteoporosis. Calcif Tissue Int. 2022;110(5):546-561. DOI: 10.1007/s00223-021-00885-6
2. Marrani E, Giani T, Simonini G, Cimaz R. Pediatric Osteoporosis: Diagnosis and Treatment Considerations. Drugs. 2017;77(6):679-695. DOI: 10.1007/s40265-017-0715-3
3. Jovanovic M, Guterman-Ram G, Marini JC. Osteogenesis Imperfecta: Mechanisms and Signaling Pathways Connecting Classical and Rare OI Types. Endocr Rev. 2022;43(1):61-90. DOI: 10.1210/endrev/bnab017
4. Зарипова А.Р., Надыршина Д.Д., Хусаинова Р.И. Спектр и частоты патогенных изменений у пациентов с несовершенным остеогенезом из Республики Башкортостан. Медицинская генетика. - 2022. - Т.21.- №9. - С.41-44. DOI: 10.25557/2073-7998.2022.09.41-44
5. Rossi V, Lee B, Marom R. Osteogenesis imperfecta: advancements in genetics and treatment. Curr Opin Pediatr. 2019;31(6):708-715. DOI: 10.1097/MOP.0000000000000813
6. Jovanovic M, Marini JC. Update on the Genetics of Osteogenesis Imperfecta. Calcif Tissue Int. 2024;115(6):891-914. DOI: 10.1007/s00223-024-01266-5
7. Меркурьева Е.С. Клинико-генетические характеристики изолированных и синдромальных форм несовершенного остеогенеза: Дис. … канд. мед. наук. - Москва; 2024. Доступно по: https://api.med-gen.ru/site/assets/files/3370/disser_merkureva_e_s_1.pdf. Ссылка активна на 28.03.2025 г.
8. Zaripova AR, Khusainova RI. Modern classification and molecular-genetic aspects of osteogenesis imperfecta. Vavilovskii Zhurnal Genet Selektsii. 2020;24(2):219-227. DOI: 10.18699/VJ20.614
9. van Dijk FS, Zillikens MC, Micha D, et al. PLS3 mutations in X-linked osteoporosis with fractures. N Engl J Med. 2013;369(16):1529-1536. DOI: 10.1056/NEJMoa1308223
10. Wolff L, Strathmann EA, Müller I, et al. Plastin 3 in health and disease: a matter of balance. Cell Mol Life Sci. 2021;78(13):5275-5301. DOI: 10.1007/s00018-021-03843-5
11. Zhong W, Pathak JL, Liang Y, et al. The intricate mechanism of PLS3 in bone homeostasis and disease. Front Endocrinol (Lausanne). 2023;14:1168306. DOI: 10.3389/fendo.2023.1168306
12. Hu J, Li LJ, Zheng WB, et al. A novel mutation in PLS3 causes extremely rare X-linked osteogenesis imperfecta. Mol Genet Genomic Med. 2020;8(12):e1525. DOI: 10.1002/mgg3.1525
13. Brlek P, Antičević D, Molnar V, et al. X-Linked Osteogenesis Imperfecta Possibly Caused by a Novel Variant in PLS3. Genes (Basel). 2021;12(12):1851. DOI: 10.3390/genes12121851
14. Wu Z, Feng Z, Zhu X, et al. Identification of a novel splicing mutation and genotype-phenotype correlations in rare PLS3-related childhood-onset osteoporosis. Orphanet J Rare Dis. 2022;17(1):247. Published 2022 Jun 25. DOI: 10.1186/s13023-022-02380-z
15. Qiu C, Li QW, Zhang L, Liu XL. X-linked osteogenesis imperfecta accompanied by patent ductus arteriosus: a case with a novel splice variant in PLS3. World J Pediatr. 2022;18(7):515-519. DOI: 10.1007/s12519-022-00539-z
16. Tüysüz B, Elkanova L, Uludağ Alkaya D, et al. Osteogenesis imperfecta in 140 Turkish families: Molecular spectrum and, comparison of long-term clinical outcome of those with COL1A1/A2 and biallelic variants. Bone. 2022;155:116293. DOI: 10.1016/j.bone.2021.116293
17. Apperley LJ, Albaba S, Dharmaraj P, Balasubramanian M. PLS3 whole gene deletion as a cause of X-linked osteoporosis: Clinical report with review of published PLS3 literature. Clin Dysmorphol. 2023;32(1):43-47. DOI: 10.1097/MCD.0000000000000442
18. Mancini M, Chapurlat R, Isidor B, et al. Early-Onset Osteoporosis: Molecular Analysis in Large Cohort and Focus on the PLS3 Gene. Calcif Tissue Int. 2024;115(5):591-598. DOI: 10.1007/s00223-024-01288-z
19. Aliyeva L, Ongen YD, Eren E, et al. Genotype and Phenotype Correlation of Patients with Osteogenesis Imperfecta. J Mol Diagn. 2024;26(9):754-769. DOI: 10.1016/j.jmoldx.2024.05.014
20. Costa A, Martins A, Machado C, et al. PLS3 Mutations in X-Linked Osteoporosis: Clinical and Genetic Features in Five New Families. Calcif Tissue Int. 2024;114(2):157-170. DOI: 10.1007/s00223-023-01162-4
21. Kämpe AJ, Costantini A, Mäkitie RE, et al. PLS3 sequencing in childhood-onset primary osteoporosis identifies two novel disease-causing variants. Osteoporos Int. 2017;28(10):3023-3032. DOI: 10.1007/s00198-017-4150-9
22. Shao C, Wang YW, He JW, Fu WZ, Wang C, Zhang ZL. Genetic variants in the PLS3 gene are associated with osteoporotic fractures in postmenopausal Chinese women. Acta Pharmacol Sin. 2019;40(9):1212-1218. DOI: 10.1038/s41401-019-0219-7
23. Laine CM, Wessman M, Toiviainen-Salo S, et al. A novel splice mutation in PLS3 causes X-linked early onset low-turnover osteoporosis. J Bone Miner Res. 2015;30(3):510-518. DOI: 10.1002/jbmr.2355
24. Wang L, Bian X, Cheng G, et al. A novel nonsense variant in PLS3 causes X-linked osteoporosis in a Chinese family. Ann Hum Genet. 2020;84(1):92-96. DOI: 10.1111/ahg.12344
25. Välimäki VV, Mäkitie O, Pereira R, et al. Teriparatide Treatment in Patients With WNT1 or PLS3 Mutation-Related Early-Onset Osteoporosis: A Pilot Study. J Clin Endocrinol Metab. 2017;102(2):535-544. DOI: 10.1210/jc.2016-2423
26. Neugebauer J, Heilig J, Hosseinibarkooie S, et al. Plastin 3 influences bone homeostasis through regulation of osteoclast activity. Hum Mol Genet. 2018;27(24):4249-4262. DOI: 10.1093/hmg/ddy318
27. Wesseling-Perry K, Mäkitie RE, Välimäki VV, et al. Osteocyte Protein Expression Is Altered in Low-Turnover Osteoporosis Caused by Mutations in WNT1 and PLS3. J Clin Endocrinol Metab. 2017;102(7):2340-2348. DOI: 10.1210/jc.2017-00099
28. Petit F, Longoni M, Wells J, et al. PLS3 missense variants affecting the actin-binding domains cause X-linked congenital diaphragmatic hernia and body-wall defects. Am J Hum Genet. 2023;110(10):1787-1803. DOI: 10.1016/j.ajhg.2023.09.002
29. Fahiminiya S, Majewski J, Al-Jallad H, et al. Osteoporosis caused by mutations in PLS3: clinical and bone tissue characteristics. J Bone Miner Res. 2014;29(8):1805-1814. DOI: 10.1002/jbmr.2208
30. van de Laarschot DM, Zillikens MC. Atypical femur fracture in an adolescent boy treated with bisphosphonates for X-linked osteoporosis based on PLS3 mutation. Bone. 2016;91:148-151. DOI: 10.1016/j.bone.2016.07.022
31. Kaifer KA, Villalón E, Osman EY, et al. Plastin-3 extends survival and reduces severity in mouse models of spinal muscular atrophy. JCI Insight. 2017;2(5):e89970. DOI: 10.1172/jci.insight.89970
32. Yang YS, Xie J, Wang D, et al. Bone-targeting AAV-mediated silencing of Schnurri-3 prevents bone loss in osteoporosis. Nat Commun. 2019;10(1):2958. DOI: 10.1038/s41467-019-10809-6
33. Schindeler A, Lee LR, O’Donohue AK, Ginn SL, Munns CF. Curative Cell and Gene Therapy for Osteogenesis Imperfecta. J Bone Miner Res. 2022;37(5):826-836.